CC-1 + tocilizumab

CC-1 + tocilizumab is a combination therapy where CC-1 (a PSMAxCD3 bispecific antibody) is administered with tocilizumab (an IL-6 receptor antagonist). This combination is used in experimental approaches for treating cancer, likely prostate cancer. Tocilizumab is administered to prevent cytokine release syndrome (CRS), a potentially serious side effect of bispecific antibody therapy. In experimental settings, tocilizumab (400 mg) was given at the first fever episode above 38.5°C occurring when IL-6 levels reached 20-100 pg/mL. The combination showed promising results with patients experiencing rapid and profound reduction of elevated prostate specific antigen (PSA) levels, suggesting antitumor activity against prostate cancer. Tocilizumab appears to effectively prevent the development of higher-grade CRS while allowing the bispecific antibody to maintain its therapeutic activity. This is significant because while steroids can also be used to treat severe CRS, the high doses required would likely abrogate the therapeutic activity of the bispecific antibody.

Brand names

ActemraRoActemra

Other names

PSMAxCD3 bispecific antibodyPSMAxCD-3 bispecific antibodyPSMAxCD 3 bispecific antibodyCC1CC-1CC 1